TScan Therapeutics Inc (TCRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.39+5.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TCRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus resources on developing in vivo-engineered TCR-T candidates for solid tumors, advancing two candidates to IND-enabling studies and planning Phase 1 initiation in Q4 2027.
Stated as a priority in 2 quarters including 2026-Q1 and a strategic reorganization disclosure in 2026-09-02. Management shifted focus to in vivo-engineered TCR-T for solid tumors, advancing two candidates to IND-enabling studies and plans to start Phase 1 in Q4 2027. This is a new strategic direction with active development and clear milestones, indicating delivering progress on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Currently developing methods to engineer TCR-T cells in vivo to treat solid tumors. Initial candidates are in preclinical development.”
Advance TSC-101 through Phase 1 and Phase 3 trials to prevent relapse post allogeneic hematopoietic cell transplantation, with data readouts and enrollment milestones.
Stated in 3 quarters including 2026-Q1 and 2026-Q2, with a strategic pause announced in 2026-09-02. The Phase 3 ALLOHA-2 study launched in 2026-Q2 with first patient dosed, but enrollment paused after 7 patients due to capital constraints. Phase 1 data from Cohort C remain positive. The trajectory shows mixed progress: clinical development advanced but enrollment paused, reflecting constrained delivery.
“First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028.”
“Launch Phase 3 study of TSC-101 in the second quarter of 2026.”
Begin Phase 1 clinical trials for TSC-102-A01 and TSC-102-A03 targeting additional HLA types in the second half of 2026.
Stated in 2 quarters including 2026-Q1 and a 2026-09-02 update. Management plans to initiate Phase 1 studies of TSC-102-A01 and TSC-102-A03 in H2 2026, with initial data expected in 2027. The program is progressing toward clinical trial initiation, indicating delivering progress on this priority.
“Initiation of Phase 1 study of TSC-102-A01 and TSC-102-A03 planned for the second half of 2026.”
Implement strategic prioritization and workforce reductions to produce annual cost savings of $45 million in 2026 and 2027.
Stated in 2 quarters including 2025-Q4 and 2026-09-02. Management expects $45 million annual cost savings in 2026 and 2027 from strategic prioritization and workforce reduction of ~75%, with cumulative savings of $55 million through end of 2027. The company has implemented a major reorganization, indicating delivering progress on cost savings.
“The strategic prioritization is expected to produce annual cost savings of $45.0 million in 2026 and 2027.”
Ensure existing cash resources fund current operating plan into the second half of 2027 despite capital constraints and strategic reorganization.
Stated in 3 quarters including 2026-Q1, 2026-Q2, and 2026-09-02. Management has consistently affirmed cash runway into the second half of 2027, extended to Q4 2027 after strategic reorganization. Cash on hand was $100.2 million at 2026-Q2. The trajectory shows management maintaining capital discipline and runway amid restructuring.
“Company believes existing cash resources will be sufficient to fund operations into the second quarter of 2027.”
“Company believes existing cash resources will be sufficient to fund current operating plan into the second half of 2027.”
Over the trailing year it converted 1.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.